Owlet Crecimiento futuro
Future controles de criterios 1/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Owlet de 138.6% y 18% respectivamente, mientras que el BPA crecerá en un 137.8% al año.
Información clave
138.6%
Tasa de crecimiento de los beneficios
137.79%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Medical Equipment | 16.1% |
| Tasa de crecimiento de los ingresos | 18.0% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 19 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Seeking Alpha • May 18
Owlet: Telehealth And Subscriptions Could Drive The Next Leg Of Growth
Summary Owlet remains a buy despite mixed Q1 results and lowered revenue guidance, with the stock trading near post-selloff lows. Subscription growth, particularly Owlet 360, is driving higher gross margins, offsetting declining hardware sales and supporting the company’s transition to a pediatric health platform. Profitability guidance improved significantly, with adjusted EBITDA now expected at $7-$9 million, reflecting a sharper focus on profitable markets and cost control. Key risks include slowing hardware sales, elevated operating expenses, and recent CEO turnover, but OWLT’s low valuation and platform evolution offer attractive upside. Read the full article on Seeking Alpha
Actualización de narrativa • May 11
OWLT: Softer Q1 Outlook Seen Setting Up Stronger 2026 Finish
Analysts have trimmed their price target on Owlet stock to $15 from $20, citing Q1 guidance that came in below expectations, while highlighting that 2026 guidance still lines up with prior views and points to a potentially stronger second half of that year. Analyst Commentary Bearish analysts are signaling a more cautious stance on Owlet after recent guidance, using the reduced price target as a way to reset expectations while still acknowledging longer term potential.Actualización de narrativa • Apr 20
OWLT: Softer Q1 Outlook Expected To Set Up Stronger Second Half 2026
Analysts have lowered their price target on Owlet to $15 from $20, citing slightly softer Q1 guidance versus expectations. They also note that current management guidance indicates the second half of 2026 could be more robust.Actualización de narrativa • Apr 05
OWLT: Guidance And Partnerships Are Expected To Support A Stronger Second Half 2026
Analysts have revised Owlet's price target to $15, down from $19, reflecting mixed near term guidance and updated models that still indicate the possibility of stronger performance in the longer term. Analyst Commentary Recent research updates on Owlet point to a more cautious tone, even as some longer term expectations remain in place.Actualización de narrativa • Mar 22
OWLT: Updated Modeling And Healthcare Partnerships Will Support Stronger Second Half 2026
Analysts have updated their view on Owlet, trimming the consolidated price target to $15 as they factor in softer Q1 guidance, a higher assumed P/E multiple and lower projected revenue growth and profit margins, while still highlighting expectations for a stronger second half of 2026. Analyst Commentary Recent research highlights a more measured tone around Owlet, with some price targets recalibrated as analysts balance solid past execution with softer near term guidance and updated valuation assumptions.Actualización de narrativa • Mar 08
OWLT: Updated Modeling And New Healthcare Partnerships Will Support Future Upside Potential
Analysts have adjusted their outlook on Owlet, trimming the price target from $14 to $13 as they factor in updated expectations for growth, profitability, and future P/E assumptions that are informed by recent research highlighting mixed near term guidance alongside longer term projections that are described as steady. Analyst Commentary Recent Street research reflects a mixed but increasingly cautious tone around Owlet, with some bearish analysts trimming price targets as they reassess growth visibility and execution risk against current valuation.Actualización de narrativa • Feb 22
OWLT: Updated Modeling And FDA Pathways Will Support Future Upside Potential
Analysts have lifted their price target on Owlet to $19 from $15, citing updated modeling assumptions following a transfer of coverage. Analyst Commentary Recent research points to a reset in expectations around Owlet, with updated modeling used to support a US$19 price target.
Actualización de narrativa • Feb 07
OWLT: Additional Liquidity And Partnerships Will Extend Funding Runway
Analysts have lifted their price target on Owlet to US$20 from US$15, citing updated models that factor in recent Street research highlighting a refreshed coverage framework and additional liquidity that supports the company’s plans. Analyst Commentary Bullish analysts are pointing to recent price target revisions as a sign of growing confidence in Owlet’s ability to execute on its plans, especially as fresh research coverage and additional liquidity are incorporated into updated models.Artículo de análisis • Feb 05
Some Owlet, Inc. (NYSE:OWLT) Shareholders Look For Exit As Shares Take 31% Pounding
Owlet, Inc. ( NYSE:OWLT ) shares have retraced a considerable 31% in the last month, reversing a fair amount of their...
Actualización de narrativa • Jan 24
OWLT: Liquidity And New Coverage Models Will Support Future Execution
Narrative Update: Owlet Analyst Price Target Shift Analysts have lifted their price target on Owlet from US$16 to US$17, reflecting updated models that factor in recent target increases on the Street and comfort with assumptions around fair value, discount rate, and a higher future P/E multiple. Analyst Commentary Recent Street research has tilted constructive on Owlet, with bullish analysts lifting price targets and updating their models following new company information and a transfer of coverage.Actualización de narrativa • Jan 09
OWLT: Liquidity And Regulatory Progress Will Support Execution While Risks Remain
Analysts have lifted their price target on Owlet to US$16.00 from US$14.88, citing refreshed models that factor in recent price target increases from firms updating coverage and highlighting added liquidity to support R&D into 2026. Analyst Commentary Recent Street research has trended constructive on Owlet, with higher price targets reflecting refreshed coverage models and a focus on liquidity and execution into 2026.Actualización de narrativa • Dec 15
OWLT: FDA Focus And Global Expansion Will Shape Balanced Risk Profile
Analysts have raised their fair value estimate for Owlet from $11.00 to $14.00 per share, citing stronger projected revenue growth, improved liquidity from a recent stock offering, and an FDA highlighted competitive moat that supports a higher long term price target. Analyst Commentary Recent research commentary has underscored a more constructive outlook on Owlet, with price targets moving higher following what was described as a solid quarter and improved balance sheet flexibility.Artículo de análisis • Dec 05
There's Reason For Concern Over Owlet, Inc.'s (NYSE:OWLT) Massive 67% Price Jump
Owlet, Inc. ( NYSE:OWLT ) shares have continued their recent momentum with a 67% gain in the last month alone. The...Actualización de narrativa • Dec 01
OWLT: Regulatory Momentum And FDA Approval Will Drive Market Leadership Forward
Analysts have increased their price target for Owlet to $15.50 from $12.00, citing a solid quarter, improved liquidity, and the company's status as the only FDA-approved over-the-counter infant monitoring device as key drivers for their more favorable outlook. Analyst Commentary Recent analyst perspectives on Owlet reflect a mixed but largely positive sentiment following the company's most recent financial results and regulatory developments.Actualización de narrativa • Nov 17
OWLT: Regulatory Approvals And Increased Liquidity Will Support Long-Term Market Leadership
Analysts have raised their price target for Owlet from $13.20 to $14.83. They cite stronger revenue growth, improved profitability, and increased liquidity following the company's solid recent quarter.Artículo de análisis • Oct 07
Further Upside For Owlet, Inc. (NYSE:OWLT) Shares Could Introduce Price Risks After 31% Bounce
Owlet, Inc. ( NYSE:OWLT ) shares have had a really impressive month, gaining 31% after a shaky period beforehand. The...Actualización de narrativa • Aug 09
Telehealth Partnerships And AI Insights Will Broaden Digital Health Markets
Driven by strong consumer demand for its FDA-cleared Dream Sock and a unique competitive position, analysts have raised Owlet’s price target from $12.30 to $13.20. Analyst Commentary The $300 Dream Sock is currently a best-selling smart baby monitor on Amazon, demonstrating strong consumer traction.Artículo de análisis • Jun 14
Investors Still Aren't Entirely Convinced By Owlet, Inc.'s (NYSE:OWLT) Revenues Despite 34% Price Jump
Owlet, Inc. ( NYSE:OWLT ) shares have continued their recent momentum with a 34% gain in the last month alone. The last...
Nueva narrativa • Apr 10
Dream Sock, BabySat, And Company360 Will Expand Global Healthcare Access
Owlet's FDA and CE approvals pave the way for global market expansion, boosting international revenue potential.Artículo de análisis • Oct 18
Many Still Looking Away From Owlet, Inc. (NYSE:OWLT)
Owlet, Inc.'s ( NYSE:OWLT ) price-to-sales (or "P/S") ratio of 1x might make it look like a strong buy right now...Artículo de análisis • Jul 18
Investors Continue Waiting On Sidelines For Owlet, Inc. (NYSE:OWLT)
With a price-to-sales (or "P/S") ratio of 0.7x Owlet, Inc. ( NYSE:OWLT ) may be sending very bullish signals at the...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 186 | 4 | N/A | N/A | 1 |
| 12/31/2027 | 145 | -1 | N/A | 2 | 5 |
| 12/31/2026 | 120 | -6 | N/A | -4 | 5 |
| 3/31/2026 | 107 | -48 | -11 | -10 | N/A |
| 12/31/2025 | 106 | -42 | -12 | -11 | N/A |
| 9/30/2025 | 100 | -42 | -8 | -7 | N/A |
| 6/30/2025 | 90 | -52 | -14 | -13 | N/A |
| 3/31/2025 | 84 | -17 | -15 | -14 | N/A |
| 12/31/2024 | 78 | -17 | -12 | -11 | N/A |
| 9/30/2024 | 79 | -11 | -16 | -16 | N/A |
| 6/30/2024 | 66 | -11 | -14 | -13 | N/A |
| 3/31/2024 | 58 | -19 | -18 | -18 | N/A |
| 12/31/2023 | 54 | -33 | -24 | -24 | N/A |
| 9/30/2023 | 45 | -49 | -32 | -32 | N/A |
| 6/30/2023 | 53 | -61 | -43 | -42 | N/A |
| 3/31/2023 | 58 | -63 | -64 | -63 | N/A |
| 12/31/2022 | 69 | -79 | -83 | -81 | N/A |
| 9/30/2022 | 55 | -84 | -79 | -77 | N/A |
| 6/30/2022 | 69 | -99 | -83 | -81 | N/A |
| 3/31/2022 | 75 | -93 | -64 | -61 | N/A |
| 12/31/2021 | 76 | -72 | -43 | -41 | N/A |
| 9/30/2021 | 99 | -53 | -41 | -40 | N/A |
| 6/30/2021 | 89 | -20 | -19 | -18 | N/A |
| 3/31/2021 | 82 | -16 | -8 | -7 | N/A |
| 12/31/2020 | 75 | -11 | -1 | 0 | N/A |
| 12/31/2019 | 50 | -18 | N/A | -16 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que OWLT siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que OWLT siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que OWLT siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (18% al año) de OWLT crezcan más rápidamente que los del mercado US (11.7% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 18% al año) de OWLT crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de OWLT se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/24 20:17 |
| Precio de las acciones al final del día | 2026/05/22 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Owlet, Inc. está cubierta por 8 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Allen Lutz | BofA Global Research |
| James Suva | Citigroup Inc |
| Ilya Zubkov | Freedom Broker |